Andrew Payne

Andrew Payne has over 20 years of work experience in the pharmaceutical and biotechnology industry. Andrew currently holds the position of VP Project Biology at Exscientia, a role they have held since January 2022. Prior to that, they served as the Head of Discovery Biology at Exscientia starting in July 2019. From July 2018 to July 2019, Andrew worked as the Collaborations Pharmacology Director at Exscientia. Before joining Exscientia, they had a long tenure at UCB, starting in 2003. At UCB, Andrew held various positions, including Senior Group Leader of the Primary Pharmacology Group. Andrew led a team of pharmacologists and was responsible for developing cellular assays to support drug discovery, with a focus on autoimmune disease. Andrew was also involved in the clinical development of seletalisib, a PI3Kdelta selective inhibitor. Andrew's work experience also includes holding the role of Group Leader at UCB from 2003 to 2018. Prior to joining UCB, they worked at Oxford Glycosciences as a Group Leader from November 2001 to April 2003 and at Prolifix Ltd as a Senior Scientist/Group Leader from September 1998 to September 2001.

Andrew Payne obtained their PhD in Antifungal Discovery - target identification and assay development from the University of Bristol, where they studied from 1995 to 1998.